Axsome reports third-quarter 2026 results, starts Phase 3 smoking cessation trial
Total net product revenue reached $259.7 million as Axsome began a Phase 3 trial of AXS-05 for smoking cessation and reported progress across its CNS pipeline.
SEC filing